Sign in
Taking people in United StatesNo phase

Bone marrow cells added to hip arthroscopy for labral tear and hip impingement

Looks at bone marrow concentrate during hip surgery for labral tears and impingement.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
Status
Recruiting
People taking part
400 people, planned
Started
6 Sept 2019
Expected to end
30 Jun 2027
Type of study
Observational, 2 groups
Treatments tested
  • BMAC
Record updated
27 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a torn rim of cartilage in the hip socket (labral tear) who are having keyhole hip surgery (arthroscopy) to repair it.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Hip symptoms that fit a labral tear, such as catching, clicking, popping or pain when sitting or bending the hip. The tear must show on MRI and/or MRA. The symptoms must not come from another sudden problem in or around the hip.
Biomarker or test result
Hip X-rays and MRI and/or MRA must be available. They must show a labral tear.

Main reasons for not taking part

  • People who do not speak English
  • Infection throughout the body
  • Being on heparin, a blood thinner
  • Pregnancy
  • Hip symptoms caused by another problem, such as a fracture, joint infection, bone death in the hip, or low back pain

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18 or older: patients of any age have the capacity to potentially benefit from labral repair
  • Symptoms consistent with a tear of the acetabular labrum (i.e., catching, clicking, popping, pain with sitting, episodic pain, pain with hip flexion, adduction, and/or internal rotation): asymptomatic labral tears do exist in the general population however there is not definitive evidence to suggest treatment of asymptomatic tears is beneficial
  • Symptoms not due to some other acute process in or around the hip (including septic arthritis, osteonecrosis, hemarthrosis, iliotibial band syndrome, fractures of the femoral neck or head, fractures of the acetabulum, greater trochanteric pain syndrome, sacroiliac joint pain, piriformis syndrome, low back pain associated with hip pain and not knee nor acute low back injury): certain conditions are not treatable by either arthroscopy or physical therapy. Some of these conditions can be managed with physical therapy but not arthroscopy
  • Availability of hip radiographs and magnetic resonance imaging (MRI and/or MRA): needed to assess eligibility
  • Evidence of labral tear on MRI and/or MRA: documentation of acetabular labrum tear
  • Willingness to participate and ability to understand and sign informed consent document: ability to understand study and consent willingly
  • Returning subjects enrolled in protocol 2017P001391/PHS

Who cannot take part

  • Pregnant women/fetuses: although surgery can be performed on pregnant women, pregnant women are excluded under federal regulations
  • Systemic infection: surgery is generally contraindicated when systemic infection is present
  • Systemic heparinization: the vascularity of the bone and adjacent tissues is significant, posing a potential problem for bleeding when the patient is anti-coagulated
  • Non-English speaking subjects: PROMs are only validated in English

Where in United States

  • MGH, Massachusetts General HospitalBoston, United StatesContact: Scott D Martin, MDTaking people

About the trial

What the trial wants to find out

Femoro-acetabular impingement is a well known cause of damage to the acetabular labrum and chondrolabral junction. Additionally, it has been proposed that disruption of hip biomechanics resulting from a labral tear causes a faster progression towards osteoarthritis (OA). This progression has been observed to begin with breakdown of the chondrolabral junction with later development of diffuse osteoarthritis. Use of hip arthroscopy has increased dramatically in recent years to treat symptomatic labral tears and potentially avoid the morbidity and cost associated with hip osteoarthritis.

Read full original descriptionShow less

Correction of labral pathology presents a technical challenge and many techniques currently exist. Increased understanding of the structure-functional relationship dictated by labral anatomy has led to the development of methods aimed at restoring functional anatomy by re-establishing the labrum's native position and contour on the rim of the acetabulum. Therefore, akin to repairing a torn meniscus in the knee, restoring the anatomic footprint of a torn labrum will reconstitute normal joint biomechanics.

Despite the advances in techniques for labral repair, strategies for mitigating or repairing damage to the chondrolabral junction do not yet exist. This area has been shown to consist of hyaline and fibro cartilage. Many techniques for cartilage repair exist, although most are not feasible due to technical challenges specific to the hip joint.

The management of articular cartilage defects is one of the most challenging clinical problems for orthopaedic surgeons. Articular cartilage has a limited intrinsic healing capacity, and pathology frequently results in gradual tissue deterioration. Currently, the standard surgical intervention for end-stage degenerative joint pathology is total joint replacement. Early surgical interventions for symptomatic cartilage lesions including cell based therapies such as autologous chondrocyte implantation (ACI), bone marrow aspirate concentrate (BMAC) implantation, or microfracture have been suggested to restore normal joint congruity and minimize further joint deterioration. Techniques such as ACI, which have been successfully used in the knee joint, have limited application in the hip due to the technical difficulties of open procedures.

The 2 groups in the trial

  • BMAC Application

    Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair. BMAC application at the time of arthroscopic labral repair.

    Treatment: BMAC

  • No BMAC Application

    Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair. No BMAC application at the time of arthroscopic labral repair.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective PROMs Outcomes in Arthroscopic Acetabular Labral Repair With and Without Application of Platelet-Rich Plasma (PRP) Harvested From the Body of the Ilium
Plain-language title
Bone marrow cells added to hip arthroscopy for labral tear and hip impingementGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 October 2025